Edoxaban

• UNSPSC Description:

  Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research[1].

• Target Antigen:

  Factor Xa; Thrombin

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/edoxaban.html

• Purity:

  99.81

• Solubility:

  DMSO : 10 mg/mL (ultrasonic)

• Smiles:

  O=C(N(C)C)[C@@H](CC1)C[C@H]([C@H]1NC(C(NC(C=C2)=NC=C2Cl)=O)=O)NC(C3=NC(CC4)=C(CN4C)S3)=O

• Molecular Weight:

  548.06

• References & Citations:

  [1]Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.Authorea. 2023 Apr 17.|Elife. 2022 Mar 23:11:e77444.|LabMed. 2024 Nov 18.|Molecules. 2023 Feb 28.|Thromb Res. 2021 Jan;197:141-143.|Virology. 2023 Jun 21.|PLoS One. 2024 May 15;19(5):e0292628.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  480449-70-5